Reply to K. Hashimoto and A. Shimomura
- 1 May 2021
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (13), 1507-1508
- https://doi.org/10.1200/jco.20.03477
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast CancerJournal of Clinical Oncology, 2021
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Journal of Clinical Oncology, 2020
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008